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Endovascular repair of mycotic aortic aneurysms
Karl Sörelius, MD,a Kevin Mani, MD,a Martin Björck, MD, PhD,a Rickard Nyman, MD, PhD,b and
Anders Wanhainen, MD, PhD,a Uppsala, Sweden
Purpose: We report our single-center experience of early and midterm outcome after endovascular repair of mycotic aortic
aneurysms (MAA).
Methods: Case records were retrospectively reviewed of 11 patients who underwent endovascular repair of 13 MAAs
between 2000 and 2007. The aneurysms were localized in the aortic arch in 1 patient, descending thoracic aorta in 4,
suprarenal abdominal aorta in 3, and infrarenal abdominal aorta in 5.
Results: Mean follow-up was 27 months. A bleeding aortoesophageal fistula resulted in one in-hospital death <30 days.
Three patients died later: one each of sepsis, stent migration that caused intestinal ischemia, and an unknown cause. Two
patients had recurrent sepsis postoperatively but no vascular complications, two had elevated inflammatory markers
during follow-up but were asymptomatic, and three patients had an uneventful follow-up.
Conclusions:Endovascular treatment for MAA was feasible, with acceptable perioperative mortality and midterm outcome
in this single-center case series. Recurrent sepsis and late relapse with a second MAA occurred, indicating the need of
long-term antibiotic therapy and follow-up, as well as the possible need for secondary open repair in selected cases.
Further research is warranted to evaluate long-term outcome. (J Vasc Surg 2009;50:269-74.)Mycotic aortic aneurysm (MAA) is a rare but life-
threatening disease, with an incidence of about 0.65% to 2%
of all aortic aneurysms.1,2 The disease has a very poor
prognosis for several reasons: MAAs have an increased
tendency to grow rapidly and to rupture,3 and patients with
MAA often have severe comorbidities (eg, immunosup-
pression) and coexisting sepsis.4 Conventional surgical
treatment, which consists of a radical operation with resec-
tion of the aneurysm, extensive local débridement, and
revascularization by in situ reconstruction or extra-
anatomic bypass is the gold standard but carries a high
mortality. Open surgery is also associated with morbidity
and risk for fatal late complications, in particular, aortic
stump blow-out.5 Furthermore, a more variable and pre-
carious location of the aneurysms sometimes makes surgical
repair very demanding or even impossible.6
Endovascular aneurysm repair (EVAR) is a less invasive
but controversial alternative to conventional open repair of
MAA. A major disadvantage is that the infected tissue,
including the aneurysm itself, is not resected, which may
facilitate reinfection, recurrent sepsis, and infection of the
endoprosthesis. Another drawback is that representative
microbiologic cultures from the infected tissue are not
harvested, making the diagnosis more dubious and the
postoperative antibiotic strategy less precise. However, a
less invasive treatment may reduce early operative mortality
and morbidity, especially in high-surgical-risk patients. The
effect on late complications may also differ. EVAR for MAA
may be considered a permanent treatment or a bridge to
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of emergency and sepsis, to be more permanently treated
later on with elective open repair.
Earlier reports on EVAR for MAA have shown prom-
ising results; however, only a few case reports and small
series7 with limited follow-up have been published. The
crucial question of durability therefore remains unan-
swered. The aim of this single-center study was to analyze
early and midterm outcome of endovascularly treated
MAA.
METHODS
All patients treated for MAA at Uppsala University Hos-
pital between January 2000 and December 2007 were iden-
tified by scrutinizing four different data sources: The Swed-
vasc registry, the registry of the Radiological Department, the
In-Patient Registry of the University Hospital, and a specific
list updated continuously by the investigators. Case records
were reviewed retrospectively. Patient characteristics (sex, age,
medical history, symptoms, concurrent infection, and results
of microbiologic cultures), aneurysm characteristics, treat-
ment method, early and late complications, and survival were
evaluated. The diagnosis of MAA was based on a combination
of clinical presentation, results of hematologic tests and cul-
tures, and radiologic findings on computed tomography
(CT), for example, saccular multilobular aneurysms or eccen-
tric aneurysms with narrow neck, rapid expansion, periaortic
gas formation within the aneurysm thrombus, and periaortic
soft tissue mass.8
Patients were reassessed postoperatively with a clinical
examination, hematologic tests, and imaging at 1, 6, and
12 months, and then annually thereafter. If a complication
was suspected, more frequent evaluations or reinterven-
tions were performed. Postoperative imaging was primarily
performed with CT, but could be replaced with ultrasound
(US) imaging in infrarenal aneurysms with no clinical sign
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fluorodeoxyglucose positron emission tomography/CT
(FDG-PET/CT) was performed.
Survival data were obtained from the Swedish national
population registry in July 2008. Survival analysis was per-
formed according to Kaplan-Meier method by using SPSS
16 software (SPSS, Chicago, Ill).
RESULTS
Patient characteristics. We identified 12 patients
treated for MAA. One patient treated with open repair was
excluded, and 11 patients (8 men) with 13 MAAs treated
endovascularly were the basis of this report. Mean age was
70 years (range, 50-80 years). Five patients had predispos-
ing factors affecting the immune system, including immu-
nosuppressive therapy (n  2), diabetes (n  2), and renal
failure requiring dialysis (n  1).
Clinical presentation, laboratory, and radiologic
findings. All patients had pain and elevated levels of in-
flammatory markers (leukocytosis or C-reactive protein, or
both) as well as typical radiologic findings for MAA at
presentation, including saccular aneurysm in 10, periaortic
inflammation in 3, rapid expansion in 2, periaortic soft
tissue mass in 2, and eccentric aneurysm with narrow neck
in 1. Nine had fever, and six had miscellaneous other
symptoms, including weight loss, diarrhea, recurrens pare-
sis, hematemesis, dysphagia, and nausea. Seven patients had
a concurrent infection comprising abscess in the iliopsoas
muscle in 2, tuberculosis in 2, osteitis/spondylitis in 1, soft
tissue infection in 1, and enteritis in 1. Positive blood-
cultures in six patients showed Salmonella species in 2,
Mycobacterium malmoense in 2, Staphylococcus aureus in 1,
and Bacillus cereus in 1 (Table). Five patients had negative
cultures, of whom two were treated with broad-spectrum
antibiotics before culture. One patient with antibiotic treat-
ment before culture had a recent history of Salmonella-
positive gastroenteritis, and one patient without prior anti-
biotic therapy had a coexisting soft-tissue infection.
Location and rupture. The aneurysms were localized
in the aortic arch in 1 patient, descending thoracic aorta in
4, suprarenal abdominal aorta in 3, and infrarenal abdom-
inal aorta in 5 (Table 1). One patient had two separate
mycotic aneurysms in the descending thoracic aorta and
infrarenal abdominal aorta at the time of diagnosis. In one
patient, a suprarenal mycotic aneurysm developed 2.5 years
after the treatment of an infrarenal MAA. Five aneurysms
presented with rupture, which was contained in three, and
eight were without signs of rupture (Fig 1).
Surgical treatment. A tubular TAG stent graft (W. L.
Gore & Assoc, Flagstaff, Ariz) was used in the treatment of
six aneurysms (Fig 2), of which one was combined with an
extra-anatomic deviation of the left subclavian and carotid
arteries comprising a carotid–carotid crossover and a left
carotid–subclavian bypass. Seven MAAs were treated with a
bifurcated Excluder (W. L. Gore & Associates) or Zenith
(Cook Inc, Bloomington, Ind) stent graft. One of these
required an extra-anatomic deviation of the visceral arteries,
which was done in a one-step procedure with a transperi-toneal approach, using a Dacron prosthetic graft with in-
flow from the infrarenal aorta (Table 1). Two patients with
a concurrent abscess in the iliopsoas muscle were treated
with drainage, and one patient with a soft tissue infection in
the first toe required an amputation.
Medical treatment. All patients were given antibiotics
preoperatively and postoperatively, initially with broad-
spectrum antibiotics intravenously and later, when dis-
charged from the hospital, oral treatment guided by culture
results, when available. Antibiotic therapy was administered
after consultation with infectious disease specialists. Pa-
tients with negative cultures received broad-spectrum anti-
biotic therapy based on clinical suspicion of infective agent.
Seven patients received antibiotic therapy throughout the
follow-up period or until death. Three patients stopped
antibiotic therapy at 2, 6, and 18 months. A new MAA
developed in one of these patients, who ultimately died
because of complications of treatment. The other two had
raised levels of inflammatory markers during follow-up but
were asymptomatic.
Follow-up and outcome. Mean follow-up (time from
repair until data was retrieved in July 2008) among survi-
vors was 27 months (range, 13-47 months). No patient was
lost to follow-up. No evidence of late prosthetic graft
infection was seen on postoperative CT (performed in all
patients) or PET-CT (performed in two patients). Accord-
ing to Kaplan-Meier analysis, 1-month survival was 91%,
and 1-year survival was 73% (Fig 3).
Outcome for all patients is presented in the Table 1.
One death occurred 30 days postoperatively: a patient
treated with a tubular stent graft for an MAA in the de-
scending thoracic aorta had a fatal bleeding from an aor-
toesophageal fistula on day 30. Two additional patients
died1 year. One patient with end-stage renal disease and
active tuberculosis who was treated with a tubular stent
graft for an MAA in the descending thoracic aorta suddenly
died at 3 months of an unknown cause, and one patient
treated with a bifurcated stent graft for a suprarenal MAA
died of sepsis at 8 months. At 2.5 years after a successful
endovascular repair of an infrarenal MAA and after 18
months of antibiotic treatment, a new mycotic aneurysm
developed in the suprarenal aorta in one patient. This was
also treated endovascularly, but the patient died 14 days
after this second intervention because of occlusion of the
superior mesenteric artery due to stent migration that
caused intestinal ischemia. The last three patients men-
tioned were all immunosuppressed because of steroid tre-
atment for polymyalgia rheumatica, immunosuppressive
treatment after renal transplantation, or renal failure requir-
ing dialysis, and they all had a poor outcome (Table).
Three of the six culture-positive patients died: one each
of new MAA with postoperative stent migration, aortoe-
sophageal fistula, and sepsis; two had complications with
postoperative sepsis; and one was treated without compli-
cations. One of the culture-negative patients died of an
unknown cause, two had raised levels of inflammatory
markers, and two were treated without complications.
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fatal outcome, showing the cause of death was intestinal
ischemia and aortoesophageal fistula. Postmortem tests for
Table. Patient characteristics, treatments, and outcomes
Age Comorbidity
Aneurysm
localization Culture
77 Steroid treated
polymyalgia
rheumatica
Infrarenal aorta
and later
suprarenal
aorta
Mycobacteria
50 Renal failure with
dialysis, active
tuberculosis
Descending
thoracic
aorta
...
77 CABG 2 years earlier,
surgically and BCG
treated bladder
cancer with post-
op severe recurrent
sepsis 1 month
earlier
Infrarenal aorta B. cereus
74 Hypertension Infrarenal aorta
and
descending
thoracic
aorta
...
62 Type I diabetes since
40 years
Infrarenal aorta ...
80 ... Descending
thoracic
aorta
Staphylococci
77 Kidney
transplantation
immunosuppressive
drugs for 9 years,
tuberculosis
Suprarenal
aorta
Mycobacteria
75 Stroke, CABG 1 year
earlier
Infrarenal aorta ...
70 ... Descending
thoracic
aorta
...
68 Popliteal aneurysm
operated on 2 years
earlier
Suprarenal
aorta
Salmonella
70 Hypertension, type II
diabetes. An
infected aortic arch
aneurysm treated
with open repair
(patch) 3 months
before
endovascular
treatment
Aortic arch Salmonella
CABG, Coronary artery bypass grafting; BCG, Bacille Calmette-Guérin; CR
truncus coeliacus.bacterial colonization of the endografts were not per-formed in these patients. Postmortem examinations were
not done in one patient with unknown cause of death
because of cultural reasons or in the patient who died in a
ure Treatment (year)
Follow-up
time
(months) Outcome
Bifurcated stent graft
(2003) and
tubular stent graft
with coverage of
tr. coeliacus
(2006)
24
0.5
Dead (intestinal
ischemia due to
stent migration with
coverage of SMA)
Tubular stent graft
(2003)
3 Dead (cause
unknown)
Bifurcated stent graft
(2004)
47 Uncomplicated
Bifurcated and
tubular stent graft
(2004)
46 Uncomplicated
Bifurcated stent graft
(2005)
37 Elevated inflammatory
markers, no vascular
complications
Tubular stent graft
(2006)
1 Dead
(aortoesophageal
fistula)
Bifurcated stent graft
with coverage of
the native renal
arteries (2006)
8 Dead (sepsis)
Bifurcated stent graft
(2007)
18 Elevated inflammatory
markers, no vascular
complications
Tubular stent graft
(2007)
16 Uncomplicated
Bifurcated stent graft
with extra-
anatomic deviation
of the renal
arteries, SMA and
tr. coeliacus
(2007)
15 Recurrent sepsis, no
vascular
complications
Tubular stent graft
with extra-
anatomic deviation
of the left
subclavian and
carotid arteries
(2007)
13 Recurrent sepsis, no
vascular
complications
tained rupture; R, rupture; SMA, superior mesenteric artery; Tr. coeliacus,Rupt
...
...
CR
...
R
CR
...
CR
R
...
...clinically evident sepsis.
ing thoracic aorta.
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A MAA is a major vascular surgical challenge. Because
of the high mortality and morbidity associated with major
surgery in these diseased patients, minimally invasive endo-
vascular treatment may be a possible therapeutic alterna-
tive, especially in high-surgical-risk patients. Owing to the
rarity and variable nature of MAAs, a true comparison of
open and endovascular treatment strategies is difficult, and
the evidence for new treatment strategies will so far have to
rely on case series with adequate follow-up. A systematic
review published in 2008 by Razavi and Razavi9 identified
Fig 2. A, Postoperative computed tomography angiography and
(B) three-dimensional reconstruction after endovascular repair of a
ruptured mycotic aneurysm in the descending thoracic aorta. Same
patient as Fig 1.Fig 1. A and B, Preoperative computed tomography angiogra-
phy of a patient with a ruptured mycotic aneurysm in the descend-52 reports with a total of 91 patients treated endovascularly
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cated in the aorta. The largest case series consisted of nine
patients with 12 aneurysms. Thus, despite small numbers,
to our knowledge the current report is the largest case series
to date of endovascular repair of MAA with midterm follow-up.
The definition of an MAA as an aneurysm with proven
bacterial infection in the aortic wall creates an inherent
limitation in studies of this disease, especially when treated
endovascularly, where bacterial culture from the aortic wall
cannot be obtained without risk. In this study, as well as in
most previous reports,3,10,11 patients were included based
on a clinical diagnosis of MAA, supported by clinical pre-
sentation, results of hematologic tests and culture, and CT
findings. Anaerobic cultures are difficult to obtain, and
these patients often received early broad-spectrum antibi-
otics, which may explain the 55% rate of positive cultures (6
of 11) in the present report. A positive culture from the
aneurysm sac is obtained in 50% to 75% of the cases after
open repair of MAA,3,4,12 and the rate of positive blood
cultures in the current study conforms to previous results.
In the present report, three of four patients who died
had a positive blood culture at presentation. The correla-
tion between outcome, positive blood culture, and infec-
tious agent are contradictory in the literature.5,12 On one
hand, patients with positive blood cultures may have a more
aggressive infection associated with a poor prognosis; on
the other hand, a positive culture enables a more precise
antibiotic therapy associated with a favorable outcome.
Results of routine culture of the abdominal aortic aneurysm
wall during surgery of clinically noninfected patients may
be positive in 14% to 37%,13,14 adding to the complexity of
this issue.
The 30-day survival in this study of 91% is comparable
with the 90% result from a recent systematic review by Kan
et al,7 but the 12-month survival rate of 73% in our study
was somewhat lower than the 81% they reported. A review
based on several case reports may, however, be subject to
Fig 3. Kaplan-Meier survival plot of 11 patients with mycotic
aortic aneurysms treated endovascularly.publication bias resulting in a falsely high survival rate.MAA can be treated with open repair and in situ or
extra-anatomic bypass with excellent short-term and
long-term outcome at specialized high-volume cen-
ters.15 Most reports, however, indicate a short-term
mortality 20%,3, 4,16,17 with significant short-term and
long-term morbidity related to the operation.4,16 In a
large series of 43 surgically treated MAAs at Mayo Clinic,
survival was 82% at 1 year and 50% at 5 years, with
significant surgical morbidity.6 One study reported a
perioperative mortality of 36%,3 and another reported a
12-month mortality of 30% after open repair for MAA.5
Thus, although short-term outcome was better after
EVAR in this series compared with historical reports on
patients undergoing open repair, 1-year survival was not.
This decrease in survival during the first postoperative
year after endovascular MAA repair in our study could
indicate a crossover of survival curves. It is, however,
difficult to compare results between different case series
of MAA due to selection bias, differences in case–mix,
and low number of cases in each series.
The four patients in this study who died all had aneu-
rysms in difficult locations: two were in the suprarenal aorta
and two were in the descending thoracic aorta. A minimally
invasive approach in these patients was particularly appeal-
ing because the perioperative mortality after open repair of
suprarenal and thoracic MAAs has been much higher than
with infrarenal involvement.18 No deaths occurred among
those treated for an infrarenal MAA in the present report.
Only one patient with MAA was treated with open
repair at this center during the study period. At 61 years
old, this patient was relatively young, had a relatively low
level of comorbidities, multiple suprarenal and infrarenal
aneurysms, presented with rupture, and was not a candidate
for EVAR. For the 11 patients included in this study, open
repair was not regarded as suitable due to complicated
anatomy or patient comorbidity and fragility. This poten-
tially affects the comparability of the outcome of this study
with historic cohorts of open repair patients.
EVAR has been suggested as a bridge to definitive open
repair in treatment of MAA,19 but this option has not yet
been used in any patient in this series. The patients were
either doing too well to justify a major open procedure, or
they were so fragile with complex anatomy that such an
operation was considered too risky. Open repair is prefera-
ble in younger patients or in those with continued septic
manifestations who are considered fit for surgery. Consid-
ering the poor outcome among immunosuppressed pa-
tients, it is possible that EVAR should be regarded as a
palliative measure or bridge to open repair in this specific
patient group. However, it is evident that the presence of a
stent graft could complicate a later open repair in many
ways, and primary open repair is preferable for patients
considered eligible for this therapy.
Kan et al7 concluded that aneurysm rupture and peri-
operative fever are the only significant predictors of persis-
tent infection after EVAR of an MAA and such patients
should therefore be considered for later open repair. In our
experience, however, patients with MAA are often old, with
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seldom are considered suitable for later radical surgery.
Furthermore, until now no radiologic sign of prosthetic
graft infection has been observed among the patients
treated.
Most patients in this study had long-term antibiotic
treatment postoperatively. Still, there was a high incidence
of recurrent sepsis (three patients, one with fatal outcome),
and a second mycotic aneurysm developed in one patient 1
year after termination of 18 months of antibiotic therapy
for the first MAA. This raises the question whether the stent
graft might have caused the recurrence. It is notable, how-
ever, that the patient was well for 2.5 years while receiving
steroid treatment and the second aneurysm developed after
termination of antibiotic therapy. The duration and choice
of antibiotic therapy, and the potential need for lifelong
treatment, is an important matter for further debate, re-
quiring longer follow-up data in a larger group of patients.
CONCLUSION
In this single-center case series, endovascular repair of
MAA had acceptable rates of perioperative mortality and
midterm survival. Recurrent sepsis as well as late relapse
with a second MAA occurred, indicating the need of long-
term antibiotic therapy and follow-up, as well as the possi-
ble need for a secondary open repair in selected cases.
Further research is warranted to evaluate long-term out-
come.
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